Multiple Sclerosis and comorbidity in Corum data, Turkey

Sinan Eliaçık

Author(s)

Sinan Eliaçık Department of Neurology, Hitit University, Faculty of Medicine,Çorum,Turkey

Abstract

Objective: To analyze the demographic and clinical characteristics, treatments, and comorbidities of multiple sclerosis (MS) patients followed in Çorum province. Methodology: This study analyzed 197 patients with MS who were followed by the Department of Neurology and diagnosed with definite MS from January 2014 to January 2024. Demographic data and case information were obtained from the hospital database. Results: Out of the 197 patients, 120 (60.9%) were female, and 77 (39.1%) were male. Mean age was 35.30 ±9.3 years, and the average disease duration 10±7.8 years. Comorbid diseases included diabetes mellitus in four patients, irritable bowel syndrome in two, and ulcerative colitis in three, hypertension in four and epilepsy in only one patient. 36 (18.3%) patients were received treatment for migraine headaches. The number of patients who started neuropathic pain treatment was 24 and 35 were seen in psychiatry outpatient clinics during the follow-up. The number of patients with sleep problems was 62 (31.5%) and 14 (7.1%) had been treated for restless legs syndrome. The pre-MS smoking was present in 31 patients (15.7%). The number of patients who used alternative methods for treatment was 63 (31.9%). Conclusion: Comorbidities affect the prognosis, treatment, frequency of health care utilization, ability to work, and quality of life in MS. Polypharmacy and comorbidities increase the complexity of MS management.

Publication Details

Page(s) 1-4

DOI DOI not available

Published Journal: Rawal Medical Journal, Volume: 49, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords

Comorbidity, Vitamin D., Disability, Multiple Sclerosis, Polypharmacy, Symptom

References

McGinley MP,Goldschmidt CH,Rae-Grant AD .2021 .Diagnosis and treatment of multiple sclerosis: a review. JAMA, 325 : 765-79.

Murúa Rodríguez,Farez S,Quintana MF,FJ MF .2022 .The immune response in multiple sclerosis. Annu Rev Pathol, 17 : 121-39.

Browne P,Chandraratna D,Angood C,Tremlett H,Baker C,Taylor BV C .2014 .a growing global problem with widespread inequity. Neurology, 83 : 1022-4.

Gijsen R,Hoeymans N,Schellevis FG,Ruwaard D,Satariano WA .2001 .Causes and consequences of comorbidity: a review. J Clin Epidemiol, 54 : 661-74.

Marrie RA,Miller A,Sormani MP,Thompson A,Waubant E,Trojano M .2016 .Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology, 86 : 1446-53.

Nociti V,Romozzi M. Multiple,Sclerosis Autoimmune,Comorbidities Autoimmune .2022 .. J Pers Med, 12 : 1828-32.

Marrie RA,Reider N,Cohen J,Trojano M,Sorensen PS,Cutter G .2015 .A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Mul Scler J, 21 : 342-9.

Martínez‐Lapiscina EH,Ayuso T,Lacruz F,Gurtubay IG,Soriano G,Otano M .2013 .Cortico‐juxtacortical involvement increases risk of epileptic seizures in multiple sclerosis. Acta Neurologica Scand, 128 : 24-31.

Mirmosayyeb O,Barzegar M,Nehzat N,Shaygannejad V,Sahraian MA,Ghajarzadeh M. .2020 .The prevalence of migraine in multiple sclerosis (MS): A systematic review and metaanalysis. J Clin Neurosci, 79 : 33-8.

Sîrbu CA,Rotaru AR,Antochi FA,Plesa A,Manole AM,Roceanu AM .2024 .Headache and Other Pain Syndromes in Multiple Sclerosis: A Narrative Review. Life, 14 : 87-9.

Kaplan TB,Berkowitz AL,Samuels MA .2015 .Cardiovascular Dysfunction in Multiple Sclerosis. Neurologist, 20 : 108-114.

Lo LM,Taylor BV,Winzenberg T,Palmer AJ,Blizzard L,van der Mei I .2021 .Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis. J Neurol, 268 : 602-12.

Marrie RA .2023 .The Barancik lecture: Comorbidity in multiple sclerosis-Looking backward, looking forward. Mult Scler, 29 : 1049-56.

Ponzio M,Monti MC,Mallucci G,Borrelli P,Fusco S,Tacchino A .2023 .The economic impact of comorbidity in multiple sclerosis. Neurol Sci, 44 : 999-1008.

Zeng X,Dorstyn DS,Edwards G,Kneebone I. .2023 .The prevalence of insomnia in multiple sclerosis: A metaanalysis. Sleep Med Rev, : 101842.

Moore H,Nair KP,Baster K,Middleton R,Paling D,Sharrack B. .2022 .Fatigue in multiple sclerosis: a UK MSregister based study. Mult Scler Rel Disord, 64 : 103954.

Brüggemann F,Gross S,Süße M,Hok P,Strauss S,Ziemssen T .2023 .Polypharmacy in patients with multiple sclerosis and the impact on levels of care and therapy units. Front Neurol, 14 : 1330066.

Chapman WD,Herink MC,Cameron MH,Bourdette D. .2023 .Polypharmacy in multiple sclerosis: prevalence, risks, and mitigation strategies. Curr Neurol Neurosci Rep, 23 : 521-9.

Ghosh R,Roy D,Dubey S,Das S,Benito-León J .2022 .Movement disorders in multiple sclerosis: an update. Tremor Hyperkinetic Movements, 12 : 14-7.

Soto-Lara M,Silva-Loredo M,Monroy-Córdoba JR,Flores-Ordoñez P,Cervera-Delgadillo NG,Carrillo-Mora P .2023 .Alternative medicine therapies in neurological disorders: prevalence, reasons and associated factors. A systematic review. Complementary Therap Med, 73 : 102932.

Küçükyılmaz K. .2023 .The Role of Vitamin D in Multiple Sclerosis. Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi, 7 : 742-55.

Podlecka-Piętowska A,Sugalska M,Janiszewska K,WallSzczech A,Cyganek A,Szejko N .2022 .Complementary and alternative medicine in multiple sclerosis: a questionnaire-based study. Neurologia i neurochirurgia Polska, 56 : 428-34.

Soto-Lara M,Silva-Loredo M,Monroy-Córdoba JR,Flores-Ordoñez P,Cervera-Delgadillo NG,Carrillo-Mora P .2023 .Alternative medicine therapies in neurological disorders: prevalence, reasons and associated factors. A systematic review. Complementary Therap Med, 73 : 102932.

Ponzio M,Podda J,Pignattelli E,Verri A,Persechino B,Vitturi BK,Bandiera P,Manacorda T,Inglese M,Durando P,Battaglia MA .2024 .Work difficulties in people with multiple sclerosis. J Occup Rehab, 34 : 606-17.